Macular Degeneration Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Macular Degeneration stocks.

Macular Degeneration Stocks Recent News

Date Stock Title
Mar 18 RGNX Regenxbio Inc (RGNX) President and CEO Kenneth Mills Sells 15,000 Shares
Mar 18 ADVM Adverum Biotechnologies GAAP EPS of -$0.23 beats by $0.11
Mar 18 ADVM Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates
Mar 18 CLSD Clearside Biomedical appoints Chong as CMO
Mar 18 REGN US appeals court revives Regeneron's antitrust lawsuit against Novartis
Mar 18 CLSD Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer
Mar 17 REGN 11 Oversold Biotech Stocks To Buy Right Now
Mar 17 REGN Regeneron Pharmaceuticals Insiders Sold US$26m Of Shares Suggesting Hesitancy
Mar 14 REGN Cardiff Oncology (CRDF) Moves 20.5% Higher: Will This Strength Last?
Mar 14 CLSD Clearside Biomedical Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Line
Mar 13 REGN Regeneron Pharmaceuticals, Inc. (REGN) Leerink Partners Global Biopharma Conference (Transcript)
Mar 13 CLSD Clearside Biomedical, Inc. (NASDAQ:CLSD) Q4 2023 Earnings Call Transcript
Mar 13 RGNX Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?
Mar 13 CLSD Q4 2023 Clearside Biomedical Inc Earnings Call
Mar 13 CLSD Clearside Biomedical, Inc. (CLSD) Q4 2023 Earnings Call Transcript
Mar 13 REGN High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical Optimization
Mar 12 CLSD Clearside Biomedical Inc (CLSD) Reports Significant Licensing Revenue Growth in Q4 and Full ...
Mar 12 CLSD Clearside Biomedical GAAP EPS of -$0.08 beats by $0.01, revenue of $6.35M beats by $2.11M
Mar 12 CLSD Clearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Mar 12 REGN Regeneron Pharmaceuticals, Inc. (REGN) Management Presents at Barclays 26th Annual Global Healthcare Conference (Transcript)
Macular Degeneration

Macular degeneration, also known as age-related macular degeneration (AMD or ARMD), is a medical condition which may result in blurred or no vision in the center of the visual field. Early on there are often no symptoms. Over time, however, some people experience a gradual worsening of vision that may affect one or both eyes. While it does not result in complete blindness, loss of central vision can make it hard to recognize faces, drive, read, or perform other activities of daily life. Visual hallucinations may also occur but these do not represent a mental illness.Macular degeneration typically occurs in older people. Genetic factors and smoking also play a role. It is due to damage to the macula of the retina. Diagnosis is by a complete eye exam. The severity is divided into early, intermediate, and late types. The late type is additionally divided into "dry" and "wet" forms with the dry form making up 90% of cases.Preventive efforts include exercising, eating well, and not smoking. Antioxidant vitamins and minerals do not appear to be useful for prevention. There is no cure or treatment that returns vision already lost. In the wet form, anti-VEGF medication injected into the eye or less commonly laser coagulation or photodynamic therapy may slow worsening. Supplements in those who already have the disease may slow progression.In 2015 it affected 6.2 million people globally. In 2013 it was the fourth most common cause of blindness after cataracts, preterm birth, and glaucoma. It most commonly occurs in people over the age of fifty and in the United States is the most common cause of vision loss in this age group. About 0.4% of people between 50 and 60 have the disease, while it occurs in 0.7% of people 60 to 70, 2.3% of those 70 to 80, and nearly 12% of people over 80 years old.

Browse All Tags